19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On June 24, 2019, the United States Supreme Court decided Dutra Group v. Batterton, No. 18-266, hold...
Read More >
As a result of the COVID-19 (coronavirus) pandemic, the Federal Trade Commission’s Premerger Notifi...
Read More >
The U.S. Department of Housing and Urban Development (HUD) issued Mortgagee Letter 2020-23, dated Ju...
Read More >
I just blogged about asking for what you want and the importance of complying with notice provisions...
Read More >
The proper trigger of coverage in construction defect disputes has been addressed on several occasio...
Read More >
On October 21, 2019, significant changes to New South Wales ("NSW") security of payment laws come in...
Read More >